English | Français
English | Français
At iC BIOSOLUTIONS, through our ICB001 lead product candidate, we are setting a new standard in regenerative biologics. Our proprietary platform unlocks the regenerative and anti-inflammatory power of secretomes, the bioactive signals released by stem cells, through a safe, consistent, and infinitely scalable process. This innovation defines a new therapeutic class designed to overcome the limitations of traditional cell-based approaches.
To harness the renewable potential of stem cells, we have developed a platform that creates “infinite” producer lines for secretome generation.
Our proprietary platform, based on the iPS technology, delivers high-quality, differentiated stem cell banks under strict GMP-compliant conditions, ensuring a reliable, contamination-free, and fully scalable biological source.
Safety
Donor-independent system eliminates tissue-related variability and minimizes contamination risks
Consistent Potency
Producer cells maintain a stable and robust regenerative signature, ensuring reproducible therapeutic performance across batches
Standardization
All production originates from a well-defined GMP-compliant cell bank, enabling large-scale, standardized and clinically reliable manufacturing
Our lead product candidate ICB001 is not a cell therapy, it is a concentrated secretome, the regenerative signals naturally released by stem cells.
Starting from our GMP-compliant master cell bank, we isolate only the paracrine factors responsible for regenerative activity. By removing cells and retaining their bioactive factors only, we deliver a product that is fully characterized, standardized, and controlled.
Strong regenerative potency
Consistent composition and concentration of paracrine factors produced under GMP conditions for robust therapeutic effect.
Greater safety
An acellular, cell-free product with none of the risks associated with viable cell therapies.
Ease of use
A shelf-stable formulation that is easy to store, transport, and administer directly in the field.